Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing
Overview
Cell Biology
Molecular Biology
Affiliations
Bacteria are central to human health and disease, but existing tools to edit microbial consortia are limited. For example, broad-spectrum antibiotics are unable to accurately manipulate bacterial communities. Bacteriophages can provide highly specific targeting of bacteria, but assembling well-defined phage cocktails solely with natural phages can be a time-, labor- and cost-intensive process. Here, we present a synthetic-biology strategy to modulate phage host ranges by engineering phage genomes in . We used this technology to redirect phage scaffolds to target pathogenic and bacteria, and conversely, phage scaffolds to target by modular swapping of phage tail components. The synthetic phages achieved efficient killing of their new target bacteria and were used to selectively remove bacteria from multi-species bacterial communities with cocktails based on common viral scaffolds. We envision that this approach will accelerate phage-biology studies and enable new technologies for bacterial population editing.
Kabwe M, Tucci J, Darby I, Dashper S J Oral Microbiol. 2025; 17(1):2469890.
PMID: 40013014 PMC: 11864011. DOI: 10.1080/20002297.2025.2469890.
Exploring the principles behind antibiotics with limited resistance.
Maharramov E, Czikkely M, Szili P, Farkas Z, Grezal G, Daruka L Nat Commun. 2025; 16(1):1842.
PMID: 39984459 PMC: 11845477. DOI: 10.1038/s41467-025-56934-3.
Engineering bacteriophages for targeted superbug eradication.
Ghaznavi G, Vosough P, Ghasemian A, Tabar M, Tayebi L, Taghizadeh S Mol Biol Rep. 2025; 52(1):221.
PMID: 39934535 DOI: 10.1007/s11033-025-10332-6.
Synthesis of Headful Packaging Phages Through Yeast Transformation-Associated Recombination.
Lu C, He L, Guo Y, Wang T, Ye Y, Lin Z Viruses. 2025; 17(1).
PMID: 39861840 PMC: 11769102. DOI: 10.3390/v17010045.
Antibiotic Resistance of Strains-Searching for New Antimicrobial Agents-Review.
Michalik M, Podbielska-Kubera A, Dmowska-Koroblewska A Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861144 PMC: 11768290. DOI: 10.3390/ph18010081.